ADMA Biologics Inc. (ADMA) and Esperion Therapeutics Inc. (NASDAQ:ESPR) Comparison side by side

Both ADMA Biologics Inc. (NASDAQ:ADMA) and Esperion Therapeutics Inc. (NASDAQ:ESPR) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ADMA Biologics Inc. 16.47M 13.14 60.99M -1.34 0.00
Esperion Therapeutics Inc. 145.42M 9.36 68.30M -7.54 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of ADMA Biologics Inc. and Esperion Therapeutics Inc.


Table 2 represents ADMA Biologics Inc. (NASDAQ:ADMA) and Esperion Therapeutics Inc. (NASDAQ:ESPR)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
ADMA Biologics Inc. -370.31% -205.4% -62.4%
Esperion Therapeutics Inc. -46.97% -48.6% -35.7%

Risk & Volatility

ADMA Biologics Inc. is 194.00% more volatile than Standard and Poor’s 500 because the company has a beta of 2.94. Competitively, Esperion Therapeutics Inc.’s beta is 1.98 which is 98.00% more volatile than Standard and Poor’s 500.


4.6 and 2.4 are the respective Current Ratio and a Quick Ratio of ADMA Biologics Inc. Its rival Esperion Therapeutics Inc.’s Current and Quick Ratios are 3.9 and 3.9 respectively. ADMA Biologics Inc. has a better chance of clearing its pay short and long-term debts than Esperion Therapeutics Inc.

Analyst Recommendations

ADMA Biologics Inc. and Esperion Therapeutics Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ADMA Biologics Inc. 0 0 5 3.00
Esperion Therapeutics Inc. 0 3 3 2.50

$10.9 is ADMA Biologics Inc.’s consensus price target while its potential upside is 198.63%. Meanwhile, Esperion Therapeutics Inc.’s consensus price target is $69.17, while its potential upside is 36.86%. Based on the data given earlier, ADMA Biologics Inc. is looking more favorable than Esperion Therapeutics Inc., analysts opinion.

Insider and Institutional Ownership

ADMA Biologics Inc. and Esperion Therapeutics Inc. has shares owned by institutional investors as follows: 57.4% and 0%. Insiders owned 25.5% of ADMA Biologics Inc. shares. Competitively, Esperion Therapeutics Inc. has 2.4% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ADMA Biologics Inc. -11.35% -10.1% 23.61% -15.4% -15.4% 86.19%
Esperion Therapeutics Inc. -2.95% 17.72% 5.18% -10.13% 19.79% 6.46%

For the past year ADMA Biologics Inc. has stronger performance than Esperion Therapeutics Inc.


On 7 of the 12 factors ADMA Biologics Inc. beats Esperion Therapeutics Inc.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.